As of Thursday close, Guardant Health Inc.’s (NASDAQ:GH) stock was up $2.03, moving up 7.04 percent to $30.85. The average number of shares traded per day over the past five days has been 4,000,260 shares. 1 time new highs have been achieved over the past 5 days, with a -$19.87 fall in that time frame. In the last twenty days, the average volume was 1,757,935, while in the previous 50 days, it was 1,305,344.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, GH stock retreated -56.66%. Shares of the company fell to $27.65 on 05/12/22, the lowest level in the past month. A 52-week high of $133.82 was reached on 01/04/22 after having rallying from a 52-week low of $28.32. Since the beginning of this year, GH’s stock price has dropped by -69.16% or -$69.17, and marked a new high 2 times. However, the stock has declined by -76.95% since its 52-week high.
Guardant Health Inc. (GH) last reported insider trading activity 64 days ago on Mar 10. MERESMAN STANLEY J, the Director of the company, disposed of 4,934 shares for $58.74 on Mar 10. It resulted in a $289,823 divestment by the insider. MERESMAN STANLEY J sold 4,934 shares at an average price of $86.08 on Jan 10. The insider now owns 4,059 shares following the transaction. On Dec 10, Director MERESMAN STANLEY J sold 4,934 shares at $95.59 apiece. The transaction was valued at $471,641.
The stock’s beta is 0.70. Besides these, the trailing price-to-sales (P/S) ratio of 10.85, the price-to-book (PB) ratio of 4.87.
In the three months ended September 29, Guardant Health Inc.’s quick ratio stood at 5.60, while its current ratio was 5.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 1.76, and the total debt-to-equity ratio was 1.76. On the profitability front, the trailing twelve-month gross margin is 67.10% percent. Based on annual data, GH earned $250.74 million in gross profit and brought in $373.65 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -21.70%. Return on equity (ROE) for the past 12 months was -54.70%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. GH’s revenue rose 18.14% to $108.11 million during the quarter, while net income inched up to $96.1 million. While analysts expected Guardant Health Inc. to report -$0.97 quarterly earnings, the actual figure was -$1.06 per share, beating the consensus estimate by -9.30%. During the quarter, the company generated -$113.05 million in EBITDA. The liabilities of Guardant Health Inc. were 1.6 billion at the end of its most recent quarter ended September 29, and its total debt was $1.36 billion. The value of shareholders’ equity is $101.92 million.
This quick technical analysis looks at Guardant Health Inc.’s (GH) price momentum. With a historical volatility rate of 167.25%, the RSI 9-day stood at 18.19% on 12 May.
With respect to its five-day moving average, the current Guardant Health Inc. price is down by -39.18% percent or -$19.87. At present, GH shares trade -57.97% below its 20-day simple moving average and -70.08% percent below its 100-day simple moving average. However, the stock is currently trading approximately -53.07% below its SMA50 and -72.51% below its SMA200.
Stochastic coefficient K was 5.01% and Stochastic coefficient D was 4.46%, while ATR was 5.78. Given the Stochastic reading of 7.45% for the 14-day period, the RSI (14) reading has been calculated as 22.71%. As of today, the MACD Oscillator reading stands at -12.42, while the 14-day reading stands at -20.47.
Guardant Health Inc. (GH) has been rated Buy by analysts. According to 0 brokerage firms, GH is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Guardant Health Inc. stock as buy, with 12 recommending it as overweight.
With a median target price of $125.00, the current consensus forecast for the stock is $85.00 – $170.00. Based on these forecasts, analysts predict Guardant Health Inc. (GH) will achieve an average price target of $123.18.